OncoSil Earns Oral Slot at Major Euro Congress as Device Data Gains Traction
OncoSil secures oral presentation slot at major European endoscopy congress
OncoSil Medical (ASX: OSL) has announced that OncoSil Medical OSPREY Registry Data has been accepted for oral presentation at the European Society of Gastrointestinal Endoscopy (ESGE) Days 2026 congress in Milan, Italy. The presentation, scheduled for 14 May 2026, will be delivered by Dr Enrique Vazquez-Sequeiros from University Hospital Ramón y Cajal in Madrid, Spain.
The acceptance represents validation of the OncoSil device within the clinical and scientific community. ESGE Days is a leading global endoscopy congress, providing a platform for the company to reach key opinion leaders and potential adopting centres across Europe. The interim registry data includes findings from 64 patients with unresectable locally advanced pancreatic cancer treated with the OncoSil device alongside gemcitabine-based chemotherapy.
Acceptance at this congress signals growing clinical interest in the device and provides investors with evidence that the technology is gaining traction among medical professionals who influence treatment protocols and hospital procurement decisions.
When big ASX news breaks, our subscribers know first
What is the OSPREY registry and why does it matter
OSPREY is a post-market registry that tracks real-world outcomes for patients receiving the OncoSil device as part of their routine clinical care. The registry is multi-centre, observational, and prospective, meaning it collects data across multiple hospitals as treatments occur in everyday practice rather than controlled trial conditions.
The registry focuses on patients with unresectable locally advanced pancreatic cancer who are receiving gemcitabine-based chemotherapy. Enrolment commenced in April 2022 and remains ongoing at participating centres. Unlike randomised clinical trials, which operate under strict protocols, registries capture how treatments perform when used by general practitioners in diverse patient populations.
Real-world registries provide evidence that complements controlled clinical trials. This type of data helps support broader physician adoption by demonstrating effectiveness outside trial conditions, and can inform regulatory discussions in markets where the device is not yet approved. For investors, registry data de-risks the commercial thesis by showing the device performs as intended when used in standard medical practice.
Understanding locally advanced pancreatic cancer
Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women globally, with 500,000 new cases detected annually. The disease is typically diagnosed at a later stage, which contributes to poor prognosis and creates significant unmet medical need for effective treatments.
Locally advanced pancreatic cancer refers to tumours that have spread to nearby blood vessels or tissues but have not metastasised to distant organs. These tumours are classified as unresectable, meaning they cannot be surgically removed. Patients in this category require treatments that can control local tumour growth and potentially create opportunities for surgical resection if the tumour shrinks sufficiently.
Interim results show encouraging survival and safety profile
The interim analysis of OSPREY registry data demonstrates encouraging efficacy and safety outcomes for patients treated with the OncoSil device. 75% of patients were treated in the first-line setting, representing the initial therapy following diagnosis. In these first-line cohorts, median overall survival ranged from 20.6 to 22.0 months from the time of diagnosis.
The Local Disease Control Rate at 12 weeks post-implant was 91.4% in first-line patients, indicating that the vast majority of treated tumours remained stable or reduced in size. 7 patients proceeded to curative-intent surgical resection following treatment, suggesting the device may enable some patients to become surgical candidates who were initially deemed inoperable.
Safety outcomes were favourable, with 15.6% of patients reporting only mild, transient adverse device effects. Notably, the registry observed zero serious complications, pancreatitis, or hospitalisations attributed to the device. The combination of encouraging survival data and a favourable safety profile strengthens the commercial thesis for OncoSil, as physicians seek treatments that balance efficacy with tolerability.
| Metric | Result | Patient Group | Timepoint |
|---|---|---|---|
| Median Overall Survival | 20.6-22.0 months | First-line (75% of cohort) | From diagnosis |
| Local Disease Control Rate | 91.4% | First-line patients | 12 weeks post-implant |
| Curative-intent surgical resection | 7 patients | Full cohort | Post-treatment |
| Adverse device effects | 15.6% (mild, transient) | Full cohort | During follow-up |
Management commentary
Nigel Lange, CEO & Managing Director
“We are delighted that the OSPREY data has been accepted for presentation at ESGE Days 2026. This recognition at a leading global endoscopy congress underscores the growing clinical interest in OncoSil™ and its potential to improve outcomes for patients with unresectable locally advanced pancreatic cancer. We look forward to sharing these important data with the international medical community.”
The next major ASX story will hit our subscribers first
Commercial footprint and regulatory status
The OncoSil device holds CE Marking approval, providing marketing authorisation in both the European Union and the United Kingdom. The device has also been designated as a breakthrough device in both Europe and the United States, a classification reserved for technologies that offer significant advantages over existing treatments for life-threatening conditions.
The device is currently approved for sale in 30+ countries, with commercial treatments already undertaken across multiple European markets. The growing commercial footprint positions the company for expanded market access, with the ESGE presentation providing additional clinical evidence to support adoption among endoscopists and oncologists.
Key regulatory and commercial milestones include:
- CE Marking approval (EU and UK)
- Breakthrough device designation (Europe and US)
- Approved for sale in 30+ countries
- Commercial treatments undertaken in: Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, and the UK
The combination of regulatory approvals, breakthrough designations, and real-world clinical evidence positions OncoSil Medical to expand its commercial presence in existing markets whilst pursuing regulatory pathways in additional territories. For investors, the ESGE presentation represents an opportunity for the company to strengthen relationships with key opinion leaders who influence treatment adoption and hospital procurement decisions across Europe.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements drop.